Published in Sci Rep on February 22, 2016
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 24.31
Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol (2002) 11.99
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest (2001) 5.72
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med (2012) 3.89
CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal (2009) 3.77
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature (2013) 3.39
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol (2008) 2.84
Clinical practice. Chronic hepatitis C infection. N Engl J Med (2011) 2.54
Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol (2006) 2.50
Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J Clin Invest (2002) 2.30
Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. J Virol (2007) 2.29
Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology (2007) 2.25
Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev (1995) 2.16
The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol (2013) 1.69
Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J Lipid Res (2000) 1.57
Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus. Hepatology (2011) 1.54
Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci U S A (2013) 1.43
Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation (2006) 1.38
Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol (2010) 1.33
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology (2012) 1.26
CD36, a scavenger receptor implicated in atherosclerosis. Exp Mol Med (2014) 1.19
HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun (2007) 1.18
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients. Virol J (2012) 1.16
CD36, oxidized LDL and PPAR gamma: pathological interactions in macrophages and atherosclerosis. Vascul Pharmacol (2004) 1.13
Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J Virol (2010) 1.10
Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology (2014) 1.09
CD36 as a lipid sensor. Physiol Behav (2011) 1.09
Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. J Intern Med (2011) 1.07
Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. Hepatology (2012) 1.06
Sulfo-N-succinimidyl oleate (SSO) inhibits fatty acid uptake and signaling for intracellular calcium via binding CD36 lysine 164: SSO also inhibits oxidized low density lipoprotein uptake by macrophages. J Biol Chem (2013) 1.04
Regulation of platelet function by class B scavenger receptors in hyperlipidemia. Arterioscler Thromb Vasc Biol (2010) 1.03
Virology and cell biology of the hepatitis C virus life cycle: an update. J Hepatol (2014) 0.96
Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. BMC Microbiol (2013) 0.96
Gene expression in livers of BALB/C and C57BL/6J mice fed a high-fat diet. Toxicol Pathol (2011) 0.93
Oxymatrine inhibits hepatitis B infection with an advantage of overcoming drug-resistance. Antiviral Res (2011) 0.92
CD36 as a therapeutic target for endothelial dysfunction in stroke. Curr Pharm Des (2012) 0.90
The SR-BI partner PDZK1 facilitates hepatitis C virus entry. PLoS Pathog (2010) 0.89
Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA. Hepatology (2010) 0.88
Type I CD36 deficiency in humans is not associated with insulin resistance syndrome. Thromb Haemost (2000) 0.88
CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis. PLoS One (2012) 0.87
CD36 forms covalently associated dimers and multimers in platelets and transfected COS-7 cells. Biochem Biophys Res Commun (1997) 0.85
Generation of high-titer viral preparations by concentration using successive rounds of ultracentrifugation. J Transl Med (2011) 0.85
Targets for antiviral therapy of hepatitis C. Semin Liver Dis (2014) 0.84
CD81-receptor associations--impact for hepatitis C virus entry and antiviral therapies. Viruses (2014) 0.83
Lipids and lipid binding proteins: a perfect match. Prostaglandins Leukot Essent Fatty Acids (2014) 0.82
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. J Viral Hepat (2012) 0.81
Investigation of the factors associated with circulating soluble CD36 levels in patients with HCV-related chronic liver disease. Diabetol Metab Syndr (2013) 0.79
ACP Journal Club: review: telaprevir, boceprevir, simeprevir, or sofosbuvir improves response in HCV type 1. Ann Intern Med (2014) 0.79
Expression of human factors CD81, claudin-1, scavenger receptor, and occludin in mouse hepatocytes does not confer susceptibility to HCV entry. Biomed Res (2011) 0.78
Host APOBEC3G protein inhibits HCV replication through direct binding at NS3. PLoS One (2015) 0.78
Synthesis and structure-activity relationship of N-(2-arylethyl) isoquinoline derivatives as human scavenger receptor CD36 antagonists. Eur J Med Chem (2011) 0.76
Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies. World J Exp Med (2012) 0.76